Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.48 |
| ▸ | GLI1 | P08151 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | CCR4 | P51679 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332522 | 0.96 | SCN4A (0.50) | SCN4AGLI1DPP4ALDH1A1NOS2 | |
| SCHEMBL7123330 | 0.93 | SCN4A (0.50) | SCN4AGLI1DPP4NOS2NOS3 | |
| SCHEMBL7122076 | 0.93 | SCN4A (0.50) | SCN4AGLI1DPP4NOS2NOS3 | |
| SCHEMBL13902906 | 0.88 | SCN4A (0.47) | SCN4AGLI1DPP4NOS2NOS3 | |
| SCHEMBL31717480 | 0.82 | SCN4A (0.43) | SCN4AGLI1DPP4NOS2NOS3 | |
| SCHEMBL31717193 | 0.82 | SCN4A (0.43) | SCN4AGLI1DPP4NOS2NOS3 | |
| SCHEMBL10325970 | 0.81 | SCN4A (0.43) | SCN4AGLI1DPP4PHGDHNOS2 | |
| Hydrochloric Acid SCHEMBL31717753 | 0.81 | SCN4A (0.42) | SCN4AGLI1DPP4NOS2NOS3 | |
| SCHEMBL17676926 | 0.79 | SCN4A (0.44) | SCN4AGLI1DPP4NOS2NOS3 | |
| SCHEMBL10326194 | 0.79 | SCN4A (0.44) | SCN4AGLI1DPP4NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249682-A1 | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications | ZHENG ZHONGLI | 2007-10-25 | — | — | US | disclosed |
| US-20070249682-A1 | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications | ZHENG ZHONGLI | 2007-10-25 | — | — | US | disclosed |
| US-7173046-B2 | CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications | BIOGEN, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173046-B2 | CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications | BIOGEN, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | disclosed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249682-A1 | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications | CD40, CD40LG, TNFSF11 | SCN4A 1851/4885GLI1 4633/4885DPP4 341/4885 |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | SCN4A 4652/4885GLI1 3630/4885DPP4 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.